8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Therapeutic mechanism and clinical application of Chinese herbal medicine against diabetic kidney disease

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Diabetic kidney disease (DKD) is the major complications of type 1 and 2 diabetes, and is the predominant cause of chronic kidney disease and end-stage renal disease. The treatment of DKD normally consists of controlling blood glucose and improving kidney function. The blockade of renin-angiotensin-aldosterone system and the inhibition of sodium glucose cotransporter 2 (SGLT2) have become the first-line therapy of DKD, but such treatments have been difficult to effectively block continuous kidney function decline, eventually resulting in kidney failure and cardiovascular comorbidities. The complex mechanism of DKD highlights the importance of multiple therapeutic targets in treatment. Chinese herbal medicine (active compound, extract and formula) synergistically improves metabolism regulation, suppresses oxidative stress and inflammation, inhibits mitochondrial dysfunction, and regulates gut microbiota and related metabolism via modulating GLP-receptor, SGLT2, Sirt1/AMPK, AGE/RAGE, NF-κB, Nrf2, NLRP3, PGC-1α, and PINK1/Parkin pathways. Clinical trials prove the reliable evidences for Chinese herbal medicine against DKD, but more efforts are still needed to ensure the efficacy and safety of Chinese herbal medicine. Additionally, the ideal combined therapy of Chinese herbal medicine and conventional medicine normally yields more favorable benefits on DKD treatment, laying the foundation for novel strategies to treat DKD.

          Related collections

          Most cited references140

          • Record: found
          • Abstract: found
          • Article: not found

          Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

          Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes at high risk for cardiovascular events. We wanted to determine the long-term renal effects of empagliflozin, an analysis that was a prespecified component of the secondary microvascular outcome of that trial.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

            Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of glycaemic control.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

              Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                03 November 2022
                2022
                : 13
                : 1055296
                Affiliations
                [1] 1 Department of Emergency , China-Japan Friendship Hospital , Beijing, China
                [2] 2 Shandong College of Traditional Chinese Medicine , Yantai, Shandong, China
                [3] 3 Beijing Key Lab for Immune-Mediated Inflammatory Diseases , Institute of Clinical Medical Sciences , China-Japan Friendship Hospital , Beijing, China
                Author notes

                Edited by: Divya Bhatia, Cornell University, United States

                Reviewed by: Krishna Murthy Nakuluri, The University of Iowa, United States

                Ping Fu, Sichuan University, China

                *Correspondence: Dan-Qian Chen, chendanqian2013@ 123456163.com ; Ping Li, lp8675@ 123456163.com

                This article was submitted to Renal Pharmacology, a section of the journal Frontiers in Pharmacology

                Article
                1055296
                10.3389/fphar.2022.1055296
                9669587
                36408255
                c5d142f2-ecae-41ce-bb9a-ca83023e5d8c
                Copyright © 2022 Chen, Wu and Li.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 27 September 2022
                : 24 October 2022
                Funding
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Award ID: 82174296 82104511
                Categories
                Pharmacology
                Review

                Pharmacology & Pharmaceutical medicine
                diabetic kidney disease,chinese herbal medicine,therapeutic mechanism,clinical application,metabolism regulation

                Comments

                Comment on this article